ProMIS Neurosciences Inc
TSX:PMN
Intrinsic Value
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one
PMN
stock under the Base Case scenario is
0.54
CAD.
Compared to the current market price of 6 CAD,
ProMIS Neurosciences Inc
is
Overvalued by 91%.
ProMIS Neurosciences Inc's market capitalization is 51.5m CAD.
PMN stock price is 6 CAD.
PMN stock (0.54 CAD) is 91% less than its price (6 CAD).
PMN. Open Relative Valuation
PMN has upside potential of 333% compared to the average analyst price target.
Open Wall St Estimates
PMN's ROE (Return on Equity) has significantly increased in the last 3 years from 259% to 1 507%.
PMN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 896% to 782%.
PMN has negative Operating Income for the last twelve months.
PMN has negative Net Income for the last twelve months.
PMN's ROE (Return on Equity) for the past 12 months is very high and is equal to 1 507%.
PMN's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 782%.
PMN's short-term liabilties (9m USD) exceed its short-term assets (4m USD).
PMN's long-term liabilties (11m USD) exceed its long-term assets (4m USD).
PMN has negative Free Cash Flow for the last twelve months.
PMN has negative three-year average ROE (Return on Equity): -10 341%. The company is not efficient at transforming stockholders' equity into net income.
PMN has negative three-year average ROIC (Return on Invested Capital): -2 128%. The company is not efficient at using invested capital to generate operating income.
PMN's D/E (Debt to Equity) is very low and is equal to 0.
PMN's Altman Z-Score is very low and is equal to -16.21.
PMN doesn't generate enough operating income (-23m USD) to safely cover interest payments on its debt (23k USD).
Valuation Backtest
ProMIS Neurosciences Inc
Run backtest to discover the historical profit from buying and selling
PMN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
ProMIS Neurosciences Inc
Balance Sheet Decomposition
ProMIS Neurosciences Inc
| Current Assets | 4.4m |
| Cash & Short-Term Investments | 3.4m |
| Receivables | 41.5k |
| Other Current Assets | 1m |
| Non-Current Assets | 19.7k |
| Intangibles | 19.7k |
| Other Non-Current Assets | -10 |
| Current Liabilities | 8.7m |
| Accounts Payable | 7m |
| Accrued Liabilities | 1.7m |
| Non-Current Liabilities | 1.9m |
| Other Non-Current Liabilities | 1.9m |
Earnings Waterfall
ProMIS Neurosciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-23.1m
USD
|
|
Operating Income
|
-23.1m
USD
|
|
Other Expenses
|
2.2m
USD
|
|
Net Income
|
-20.9m
USD
|
Free Cash Flow Analysis
ProMIS Neurosciences Inc
What is Free Cash Flow?
PMN Profitability Score
Profitability Due Diligence
ProMIS Neurosciences Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
ProMIS Neurosciences Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
PMN Solvency Score
Solvency Due Diligence
ProMIS Neurosciences Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
ProMIS Neurosciences Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PMN Price Targets Summary
ProMIS Neurosciences Inc
According to Wall Street analysts, the average 1-year price target for
PMN
is 26 CAD
.
Shareholder Return
PMN Price
ProMIS Neurosciences Inc
| Average Annual Return | -6.5% |
| Standard Deviation of Annual Returns | 58.09% |
| Max Drawdown | -78% |
| Market Capitalization | 51.5m CAD |
| Shares Outstanding | 8 579 280 |
| Percentage of Shares Shorted | 0.03% |
Company Profile
ProMIS Neurosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
ProMIS Neurosciences Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 5 full-time employees. The company went IPO on 2005-09-30. ProMIS Neurosciences, Inc. is a Canada-based development-stage biotechnology company. The firm is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The firm is focused on the discovery engine, which is based on the use of two complementary algorithms: ProMIS and Collective Coordinates, which are used to predict targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. The firm is focused on developing antibody therapeutics for AD, ALS and PD. The firm has a wholly owned subsidiary is ProMIS Neurosciences (US) Inc. (ProMIS USA).
Contact
IPO
Employees
Officers
The intrinsic value of one
PMN
stock under the Base Case scenario is
0.54
CAD.
Compared to the current market price of 6 CAD,
ProMIS Neurosciences Inc
is
Overvalued by 91%.
You don't have any saved screeners yet
